Quick Answer
Entera Bio Ltd. reported Operating Income Loss of -$11.53 million for the year ending 2025.
- Entera Bio Ltd. showed a decrease of -20.3% in Operating Income Loss from 2024 to 2025.
- This data is from Entera Bio Ltd.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: -$2.34 million | Q2 2021: -$2.57 million | Q3 2021: -$3.22 million | Q1 2022: -$3.84 million | Q2 2022: -$3.25 million | Q3 2022: -$2.87 million | Q1 2023: -$2.21 million | Q2 2023: -$2.33 million | Q3 2023: -$2.39 million | Q1 2024: -$2.06 million | Q2 2024: -$2.17 million | Q3 2024: -$3.02 million | Q1 2025: -$2.56 million | Q2 2025: -$2.67 million | Q3 2025: -$3.26 million.
- Over the full 6 years of available data (2020 to 2025), Entera Bio Ltd.'s Operating Income Loss has declined by 3.2%.
- Historical annual values: Fiscal year 2025: -$11.53 million | Fiscal year 2024: -$9.59 million | Fiscal year 2023: -$8.89 million | Fiscal year 2022: -$13.02 million | Fiscal year 2021: -$12.22 million | Fiscal year 2020: -$11.17 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: